Clovis Oncology (CLVS) shares were higher Wednesday after analysts with Credit Suisse boosted the stock's rating to OUTPERFORM from NEUTRAL. The firm also hiked its price target to $41 from $19. They say the biotech company could receive a takeover offer given the potential market demand for its anti-cancer drug Rucaparib. The Credit Suisse analysts believe Clovis could be worth $35 to $41 a share on operational synergies, and $52 to $55 a share when accounting for leveraged tax benefits.
More from Video
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.